Hodgkin-Lymphome bei Kindern und Jugendlichen^{[ 1 ]}

 

 Buy Article Permissions and Reprints

Zusammenfassung

Maligne Lymphome sind nach den akuten Leukämien und den ZNS-Tumoren die dritthäufigste maligne Erkrankung bei Kindern und Jugendlichen. Mit einer sehr intensiven Polychemotherapie, der bei den Hodgkin-Lymphomen meist eine lokale Radiotherapie folgt, können heute über 90 % der Kinder und Jugendlichen mit Hodgkin-Lymphomen mit einer dauerhaften Heilung rechnen. Die im Vergleich zu anderen onkologischen Erkrankungen besonders große Zahl langzeitüberlebender Kinder und Jugendlicher rückt aber auch insbesondere beim Hodgkin-Lymphom die negativen Therapiefolgen stärker in den Blickpunkt. Die derzeitige, für jedes Stadium risikoangepasste Therapie muss daher unter dem Motto stehen: Soviel Therapie wie nötig, aber so wenig Therapie wie möglich.

Summary

Malignant lymphomas are the third most common malignancy after acute leukemias and CNS tumors in children and young adults. Intensive chemotherapy, usually followed by local radiotherapy, leads to permanent cure for over 90 % of children and young people with Hodgkin’s lymphoma. However, compared to other oncological diseases, the particularly large number of long-time survivors has brought the negative therapeutic effects of Hodgkin’s lymphoma in the spotlight. Accordingly, the risk-adapted therapy for each stage must be carried out under the motto: „As much therapy as necessary, but as little therapy as possible“.

¹ Nachdruck aus: TumorDiagnostik und Therapie 2013; 34(5): 262−265

• Literatur

• 1 Kaatsch P, Spix C. Jahresbericht 2007 Deutsches Kinderkrebsregister. Mainz 2008;
  PubMedGoogle Scholar
• 2 Schellong G et al Combined treatment strategy in over 200 children with Hodgkin’s disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82. Klin Padiatr 1986; 198: 137-146
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Donaldson SS, Link MP. Combined modality treatment with low-dos radiation and MOPP chemotherapy for children with Hodgkin’s disease. J Clin Oncol 1987; 5: 742-749
  PubMedGoogle Scholar
• 4 Dieckmann K et al Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin’s disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90. Radiother Oncol 2002; 62: 191-200
  CrossrefPubMedGoogle Scholar
• 5 Dörffel W et al Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klin Padiatr 2003; 215: 139-145
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Mauz-Körholz C et al Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110: 179-185
  CrossrefPubMedGoogle Scholar
• 7 Schellong G et al Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181-6189
  CrossrefPubMedGoogle Scholar
• 8 Neglia JP et al Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 193: 618-629
  PubMedGoogle Scholar
• 9 Schellong G, Riepenhausen M. Late effects after therapy of Hodgkin’s disease: update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 2004; 216: 364-369
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Brämswig JH et al The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin’s disease during childhood or adolescence. Cancer 1990; 65: 1298-302
  CrossrefPubMedGoogle Scholar